In the years leading up to its bankruptcy filing, the company also struggled with the growth of free or low-cost ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on ...

Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Drugs that both activate and block the GIP receptor reduce weight through different brain mechanisms, offering a new ...

Founded in 1963 by Jean Nidetch, WeightWatchers began as a weekly weight-loss support group with just 400 attendees. It quickly grew into a global phenomenon, attracting millions of members worldwide ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Following on from a remarkable study in mice, scientists have now confirmed that silencing a certain protein in muscle tissue ...

The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...